Renal involvement in IgA vasculitis; possible correlation with positive antiphospholipid antibodies

Mehrnoush Hassas Yeganeh MD, Aye Yaraghi MD, Shima Salehi MD, Khosro Rahmani MD, Vadood Javadi MD, Reza Shari MD, Hamid Hosseinzadeh MD

Pediatric Pathology Research Center, Research Institute for Children Health, SBMU, Tehran, Iran
Pediatric Resident, Mofid Children Hospital, SBMU, Tehran, Iran
Pediatric Rheumatologist, Aliasghar Children Hospital, IUMS, Tehran, Iran
Pediatric Rheumatologist, Mofid Children Hospital, SBMU, Tehran, Iran
Orthopedic Surgeon, Rowan University, Glassboro, NJ, USA

Correspondence to Reza Shari, Mofid Children Hospital, Shariati Ave, Tehran, Iran; email: shiareza@yahoo.com

ABSTRACT
IgA vasculitis is a hypersensitivity vasculitis, which is usually self-limiting. Renal involvement is the most damaging long-term complication of IgA vasculitis, happening in 20% - 100% of cases. Some factors have been reported to be associated with renal involvement in IgA vasculitis; however, no biomarker has been proved as a risk factor for renal involvement and its severity yet. We followed 48 patients with a confirmed diagnosis of IgA vasculitis for six months. We checked these patients for renal involvement by microscopic urine examination. We checked aPL antibodies in all patients on admission and 12 weeks later. Urinalysis showed renal involvement in 14 of 48 patients with IgA vasculitis (29.16%). Antiphospholipid antibodies were positive in 9 patients with IgA vasculitis and renal involvement (9 out of 14, 64.28%), while they were positive in only six patients with IgA vasculitis without renal involvement (6 out of 34, 17.64%), showing a moderate correlation between positive aLP and renal involvement in patients with IgA vasculitis, with a kappa index of 0.457. Serum aPL antibodies, as a tool to predict renal involvement in IgA vasculitis, show a sensitivity of 64.3%, a specificity of 82.4%, PPV of 60.0% and NPV of 84.8%, demonstrating that a positive serum aPL antibody can be used to positively predict the renal involvement, while a negative result is not strong enough to rule out future renal involvement.

Keywords: IgA vasculitis, antiphospholipid antibodies, lupus anticoagulant, anticardiolipin antibodies, and anti-b2 glycoprotein antibodies

Introduction
IgA vasculitis is a hypersensitivity vasculitis characterized by the deposition of IgA-containing immune complexes within the blood vessels throughout the body. The dominant clinical features include nonthrombocytopenic purpura (with lower limb dominance), abdominal pain, arthritis/arthralgia, and renal involvement (1).

Renal involvement is the most damaging long-term complication of IgA vasculitis. 20% - 100% of children with IgA vasculitis will have renal involvement (2), 80% of them present with isolated hematuria and/or proteinuria, whereas only 20% have acute nephritis or nephrotic syndrome at presentation. Renal involvement usually develops by four weeks (3). Most patients with renal involvement have a favorable prognosis. However, around 20% of these patients develop end-stage renal disease (2,4). IgA vasculitis nephritis is the only disease manifestation that may be associated with long-lasting morbidity; hence, the long-term prognosis of IgA vasculitis is mainly determined by the progression of renal involvement (4,5).

There was no financial support for this research.
The authors report no conflicts of interest regarding this manuscript. None of the authors, nor their institutions, received any payment or services from a third party for any aspect of the submitted work.
Some factors have been reported to be associated with renal involvement in IgA vasculitis, such as age at onset (older than ten years at onset), gender (male gender is a risk factor), digestive tract symptoms, persistence (for more than one month) or recurrence of purpura, WBC >15X10⁹/L and platelet count >500X10⁹/L and, upper respiratory tract infection, especially streptococcal infection with elevated ASO, and decreased C3 level (4,6). Onset at an older age (>6 years), longer interval between IgA vasculitis symptom onset and IgA vasculitis diagnosis (>8 days), presence of angioedema, recurrence of purpura, and CNS involvement are factors associated with increased risk of severe kidney disease (1). However, no biomarker has been proved as a risk factor for renal involvement and its severity yet (7).

Association between IgA vasculitis and antiphospholipid (aPL) antibodies has been first reported in 2000 (8). Since then, the presence of aPL antibodies in patients with IgA vasculitis has been reported to be associated with disease activity (9,10), and central nervous system involvement (11). However, the association between aPL antibodies and renal involvement and prognosis in IgA vasculitis remains unrevealed.

In the present study, to confirm the correlation between renal involvement in IgA vasculitis and aPL antibodies, we report the 6-month follow-up of 48 patients with IgA vasculitis.

Method
Ethics approval
The ethics committee of Shahid Beheshti Medical University (SBMU) approved this study, in accordance with ethical standards of the local committee of the SBMU’s ethics board and the Declaration of Helsinki. The ethical approval number is IR.SBMU.RETECH.REC.1397.595. We obtained informed consent from the parents of all patients.

Clinical investigation
According to 2008 criteria of EULAR-PRES for diagnosing IgA vasculitis (palpable purpura (mandatory criterion) in the presence of at least one of the following four features: diffuse abdominal pain, any biopsy showing predominant IgA deposition, arthritis or arthralgia, and renal involvement [any hematuria and/or proteinuria]) (12), 48 pediatric patients were diagnosed with and admitted IgA vasculitis at Mofid Children Hospital (SBMU, Tehran, Iran) from September 2015 to June 2017.

We considered the following criteria for diagnosing renal involvement in IgA vasculitis: (1) hematuria in urine analysis (both microscopic and gross hematuria); (2) proteinuria in urine analysis; and (3) both proteinuria and hematuria (12). We followed all patients for six months since children with no urinary pathology during the first six months after the onset of IgA vasculitis will not develop renal impairment during the long term follow-up (13).

Detection of antiphospholipid antibodies
We obtained two serum samples from all patients with IgA vasculitis to detect for aPL antibodies, the first sample on patient admission, and the second one, 12 weeks later, to make sure that the aPL antibodies are still elevated. All samples were preserved at -80°C, no more than four weeks before the detection of antiphospholipid antibodies. Laboratory assessment of antiphospholipid antibodies was based on the latest update of the classification criteria for definite antiphospholipid antibody syndrome (14). Lupus anticoagulant was detected with the Kaolin conglutination time method, whereas anticardiolipin antibodies and anti-b2 glycoprotein I antibodies were detected by enzyme-linked immunosorbent assays. Detection of positive titers of even one of these antiphospholipid antibodies was recognized as a positive result.

Statistical methods
Statistical analyses were performed using SPSS version 22.0 (IBM, New York, NY, USA). A chi-square test was used to compare the rate of positive aPL in patients with IgA vasculitis, with and without renal involvement. P-value of less than 0.05 was regarded as statistically significant.

Results
We included 48 patients with a confirmed diagnosis of IgA vasculitis based on clinical criteria and skin biopsy of the cutaneous lesions. Skin biopsy showed
neutrophilic infiltrate in the wall of small vessels, perivascular neutrophilic infiltration in the dermis, endothelial swelling, perivascular edema with RBC extravasation, and leukocytoclastic vasculitis and nuclear derbies.

Among these 48 patients, we had 31 boys and 17 girls (the ratio of boys to girls was 1.82:1), with the mean age of 6.2 ± 2.3 (5 - 9 years).

**Renal involvement**

At the time of diagnosis, the renal involvement was discovered in only 1 of the cases as microscopic hematuria. During the six-month course of follow-up, urinalysis showed renal involvement in 14 of 48 patients with IgA vasculitis (29.16%), including the first case. They included ten boys and four girls (the ratio of boys to girls was 2.5:1). All renal complications appeared within six months during the course of IgA vasculitis and included hematuria and proteinuria. All 14 patients with renal involvement showed microscopic hematuria, and just 2 cases had gross hematuria, 5 of them presented with proteinuria, and just one patient showed nephrotic-range syndrome.

**Antiphospholipid antibodies in IgA vasculitis children**

At the time of the patient admission, the aLP antibody was positive in 15 patients and negative in 33 patients. The second test was performed in all patients 12 weeks after the first test, and the result of the aPL tests was again positive in the 15 positive patients and negative in the 33 negative patients. Antiphospholipid antibodies were positive in 9 patients with IgA vasculitis who showed renal involvement (9 out of 14, 64.28%) during the follow-up, while they were positive in only six patients with IgA vasculitis without renal involvement (6 out of 34, 17.64%). Hence, the positive percentages of lupus anticoagulant, anticardiolipin antibodies, and anti-b2 glycoprotein antibodies (antiphospholipid antibodies) in serum were much higher in children with IgA vasculitis with renal involvement (P <0.01, Table 1) and there is a moderate correlation between positive aLP and renal involvement in patients with IgA vasculitis, with a kappa index of 0.457.

|                | With Renal Involvement | Without Renal Involvement | Total |
|----------------|------------------------|---------------------------|-------|
| Positive aPL   | 9                      | 6                         | 15    |
| Negative aPL   | 5                      | 28                        | 33    |
| Total          | 14                     | 34                        |       |

Based on these findings, if we use aLP for predicting renal involvement in patients with IgA vasculitis, the sensitivity is 64.3%, the specificity is 82.4%, PPV 60.0%, and NPV 84.8%.

**Discussion**

Although IgA vasculitis is a self-limiting disease in the majority of cases, the long-term prognosis of IgA vasculitis is primarily dependent on the severity of renal involvement, which may manifest as persistent hematuria or proteinuria, nephrotic or nephritic syndrome or even end-stage renal disease (15). There are some interventions, like leukocytapheresis or cyproheptadine, that can prevent or at least decrease the occurrence of renal involvement in patients with IgA vasculitis. To be effective, this prevention or delay of this renal disease needs early suspicion of renal involvement in IgA vasculitis (6).

Early diagnosis is partly relying on knowing the risk factors for renal involvement. Wang et al. in a retrospective review on Chinese children, reported several risk factors for renal involvement in IgA vasculitis patients, including onset at an older age, colder season, longer interval between symptom onset of IgA vasculitis and its diagnosis, rural residency, skin lesion recurrence, angioedema and CNS involvement (1). Several of these reported risk factors have just a statistical relationship, not a cause-effect relationship.

Chan et al. in a meta-analysis reported some factors associated with renal involvement in IgA vasculitis, such as age at onset (older than ten years at onset), gender (male gender is a risk factor), digestive tract symptoms, persistence (for more than one month) or recurrence of purpura, WBC >15×10⁹/L and platelet count >500×10⁹/L and, upper respiratory...
tract infection, especially streptococcal infection with elevated ASO, and decreased C3 level [6].

De Almeida et al., in a retrospective study, analyzed the initial prognostic factors for renal involvement in IgA vasculitis and found that the severe abdominal pain among several risk factors as the only independent variable associated with nephritis, not other forms of renal involvement (16).

Kaku et al., in a prospective study, assess risk factors associated with renal involvement in IgA vasculitis patients. This is the first study to report this relationship. They found that higher age at onset (>7 years), persistent purpura, and a decreased F XIII activity were associated with increased risk of renal involvement. They also found that corticosteroid treatment for IgA vasculitis decreased the risk of involvement in IgA vasculitis patients (4). There are controversies on this latter finding in more recent studies. Chartapisak et al., in a review, analyzed the available articles and found that corticosteroids do not prevent or alter the course of renal involvement in IgA vasculitis (3). In 2014, Davin et al. reported that prompt institution of aggressive immunosuppressive treatment could blunt the risk of renal disease progression (17). This finding, although not strongly proved yet, has an important implication that if the patient with IgA vasculitis is treated early and correctly, the risk of renal involvement will be decreased, underscoring the importance of identifying the risk factors.

Among the studies reporting these risk factors, we could not find any humoral marker associated with an increased risk of renal involvement. There are several reports of association of antiphospholipid antibodies with IgA vasculitis disease and different manifestations of this disease. Basaran Kaya et al. and Yang et al. reported IgA antiphospholipid antibodies to be associated with IgA vasculitis disease activity. They proposed that aPL antibodies may play a role in IgA vasculitis onset (9,18).

Kawakami et al. reported the association between high titer serum aPL and cutaneous leukocytoclastic angiitis in IgA vasculitis patients (19). Sokol et al. reported the association of serum and CSF aPL titers with neurologic involvement in IgA vasculitis patients (20).

Whether IgA vasculitis has a coincidental association with aPL antibodies is still poorly understood; however, it seems to be more than a coincidence. IgA vasculitis-related antibodies cause vasculitis, which exposes the endothelial phospholipids, otherwise nonexposed, allowing aPL antibodies to interact with them (21).

Our results show a moderate correlation between serum aPL antibodies and renal involvement. This correlation can not only show the positive serum aPL antibodies as a risk factor for renal involvement in IgA vasculitis patients but can also show a cause-effect relationship. In other words, this correlation may propose the aPL antibodies as a causative factor for renal involvement in IgA vasculitis.

This may have important diagnostic and treatment implications. Literature shows an earlier diagnosis of renal involvement leads to more rapid treatment establishment, which clearly improves the prognosis. If positive aPL antibodies can predict renal involvement in IgA vasculitis, it can help the earliest treatment, hence improving the prognosis more.

If we consider positive serum aPL antibody as a tool to predict renal involvement in IgA vasculitis, our study shows a sensitivity of 64.3%, a specificity of 82.4%, PPV of 60.0% and NPV of 84.8%, showing that a positive serum aPL antibody can be used to positively predict the renal involvement, while a negative result is not strong enough to rule out future renal involvement.

This study can only open a new vision into the correlation of aPL antibodies and renal involvement in IgA vasculitis patients. The main limitation of this study is the limited number of patients and lack of renal biopsy as a diagnostic and follow-up tool for renal involvement since renal biopsy was not part of our management protocol for renal complications in IgA vasculitis. Hence, we need multicenter, more extensive cohort studies to reach a better and more accurate conclusion on the relationship between serum aPL antibodies and renal involvement in IgA vasculitis patients.
Conclusion
Positive aPL antibodies in a patient with IgA vasculitis can be considered as an alarm for probable renal involvement during the course of IgA vasculitis, necessitating closer screening and follow-up for renal involvement in these patients, to diagnose and treat the nephritis earlier.

References
1. Wang K, Sun X, Cao Y, Dai L, Sun F, Yu P, et al. Risk factors for renal involvement and severe kidney disease in 2731 Chinese children with Henoch–Schönlein purpura. Medicine (Baltimore) 2018;97:1–5.
2. Davin JC. Henoch-Schönlein Purpura Nephritis: Pathophysiology, Treatment, and Future Strategy. Clin J Am Soc Nephrol 2011;6:679–689. Available at: http://cjasn.asnjournals.org/cgi/doi/10.2215/CJN.06710810.
3. Chartapisak W, Opastrakul SW, Willis NS, Craig JC, Hodson EM. Prevention and treatment of renal disease in Henoch-Schönlein purpura: a systematic review. Arch Dis Child 2009;94:132–137. Available at: http://adc.bmj.com/cgi/doi/10.1136/adc.2008.141820.
4. Kaku Y, Nohara K, Honda S. Renal involvement in Henoch-Schönlein purpura: A multivariate analysis of prognostic factors. Kidney Int 1998;53:1755–1759. Available at: http://linkinghub.elsevier.com/retrieve/pii/S008525381505986.
5. Christin NM. Identification, management of renal involvement important in Henoch-Schönlein purpura. AAP news 2014;35:11–13.
6. Chan H, Tang Y-L, Lv X-H, Zhang G-F, Wang M, Yang H-P, et al. Risk Factors Associated with Renal Involvement in Childhood Henoch-Schönlein Purpura: A Meta-Analysis. Reboldi G, ed. PLoS One 2016;11:e0167346. Available at: https://dx.plos.org/10.1371/journal.pone.0167346.
7. Hastings MC, Moldoveanu Z, Suzuki H, Berthoux F, Julian BA, Sanders JT, et al. Biomarkers in IgA nephropathy: relationship to pathogenetic hits. Expert Opin Med Diagn 2013;7:615–627. Available at: http://www.tandfonline.com/doi/full/10.1517/17530059.2013.856878.
8. Yang YH, Huang MT, Lin SC, Lin YT, Tsai MJ, Chiang BL. Increased transforming growth factor-beta (TGF-beta)-secreting T cells and IgA anti-cardiolipin antibody levels during acute stage of childhood Henoch-Schönlein purpura. Clin Exp Immunol 2000;122:285–290. Available at: http://www.embase.com/search-results?subaction=viewrecord&from=export&id=L30839107%0Ahttp://dx.doi.org/10.1046/j.1365-2249.2000.01361.x.
9. Kaya ÖB. Increased Serum Immunoglobulin A Antiphospholipid Antibody Levels in Childhood Henoch-Schönlein Purpura. Turkish J Rheumatol 2013;27:227–232. Available at: http://www.tjr.org.tr/text.php3?id=481.
10. Yang YH, Chang CJ, Chuang YH, Hsu HY, Yu HH, Lee JH, et al. Identification and characterization of IgA antibodies against β2-glycoprotein I in childhood Henoch-Schönlein purpura. Br J Dermatol 2012;167:874–881. Available at: http://doi.wiley.com/10.1111/j.1365-2133.2012.11068.x.
11. Liu A, Zhang H. Detection of Antiphospholipid Antibody in Children With Henoch-Schönlein Purpura and Central Nervous System Involvement. Pediatr Neurol 2012;47:167–170. Available at: http://dx.doi.org/10.1016/j.pediatrneurol.2012.05.024.
12. Ozen S, Pistorio A, Iusan SM, Bakkaloglu A, Herlin T, Brik R, et al. EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. Ann Rheum Dis 2010;69:798–806. Available at: http://ard.bmj.com/cgi/doi/10.1136/ard.2009.116657.
13. Pohl M. Henoch–Schönlein purpura nephritis. Pediatr Nephrol 2015;30:245–252. Available at: http://link.springer.com/10.1007/s00467-014-2815-6.
14. MIYAKIS S, LOCKSHIN MD, ATSUMI T, BRANCH DW, BREY RL, CERVERA R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006;4:295–306. Available at: http://doi.wiley.com/10.1111/j.1538-7836.2006.01753.x.
15. Edström Halling S, Söderberg MP, Berg UB. Predictors of outcome in Henoch–Schönlein nephritis. Pediatr Nephrol 2010;25:1101–1108. Available at: http://link.springer.com/10.1007/s00467-010-1444-y.
16. Almeida JLJ de, Campos LMA, Paim LB, Leone C, Koch VHK, Silva CAA. Renal involvement in Henoch-
Schönlein purpura: a multivariate analysis of initial prognostic factors. *J Pediatr (Rio J)* 2007;83:259–266. Available at: http://www.jped.com.br/conteudo/ing_resumo.asp?varArtigo=1638&cod=&idSecao=4.

17. Davin J-C, Coppo R. Henoch–Schönlein purpura nephritis in children. *Nat Rev Nephrol* 2014;10:563–573. Available at: http://dx.doi.org/10.1038/nrneph.2014.126.

18. Yang YH, Yu HH, Chiang BL. The diagnosis and classification of Henoch-Schönlein purpura: An updated review. *Autoimmun Rev* 2014;13:355–358. Available at: http://dx.doi.org/10.1016/j.autrev.2014.01.031.

19. Kawakami T, Yamazaki M, Mizoguchi M, Soma Y. High titer of serum antiphospholipid antibody levels in adult Henoch-Schönlein purpura and cutaneous leukocytoclastic angiitis. *Arthritis Rheum* 2008;59:561–567. Available at: http://doi.wiley.com/10.1002/art.23528.

20. Sokol DK, McIntyre JA, Short RA, Gutt J, Wagenknecht DR, Biller J, et al. Henoch-Schonlein purpura and stroke: Antiphosphatidyl-ethanolamine antibody in CSF and serum. *Neurology* 2000;55:1379–1381. Available at: http://www.neurology.org/cgi/doi/10.1212/WNL.55.9.1379.

21. Zhang H, Huang J. Henoch–Schönlein purpura associated with antiphospholipid syndrome. *Pediatr Nephrol* 2010;25:377–378. Available at: http://link.springer.com/10.1007/s00467-009-1300-0.